EP3179992A1 — Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

USPTO Abstract

Therapeutic compositions and methods of using the compositions, including combinations of a Bruton's tyrosine kinase (BTK) inhibitor, a phosphomositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both y- and δ-isoforms (ΡΙ3Κ-γ,δ, ΡΙ3Κ-γ, and ΡΙ3Κ-δ, a programmed death 1 (PD-1) or programmed death ligand 1 (PD-Ll) inhibitor, and/or a Janus kinase-2 (JAK- 2) inhibitor are described. In certain embodiments, the invention includes therapeutic methods of using a PD-1 monoclonal antibody and a BTK inhibitor. In other embodiments, the invention includes therapeutic methods of using a PD-Ll monoclonal antibody and a BTK inhibitor. In other embodiments, the invention includes therapeutic methods of using a PD-1 inhibitor, a BTK inhibitor, and a ΡΙ3Κ~δ inhibitor. In other embodiments, the invention includes therapeutic methods of using a PD-Ll inhibitor, a BTK inhibitor, and a ΡΙ3Κ~δ inhibitor.